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Abstract
Background Atopic dermatitis (AD) is a common inﬂammatory skin disease in both adults and children. Whilst topical
calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, have proven efﬁcacy for the treatment of AD,
it is important to involve experts to obtain their opinion on its optimal treatment.
Objective Using a modiﬁed Delphi approach, this project aimed to generate consensus amongst experts on the use of
TCIs in the treatment of AD, with a focus on the differentiation between tacrolimus and pimecrolimus.
Methods Six expert dermatologists from different European countries participated in this project based on their experi-
ence with AD and its treatment, which was evaluated by literature analysis and expert opinion. Consensus amongst the
experts was generated using a modiﬁed Delphi approach, consisting of three distinct phases, during which a web meet-
ing (June 2017), two online rounds of blinded Delphi voting (July–September 2017) and a face-to-face meeting (Novem-
ber 2017) were conducted. The consensus statements concerned two main topics: (i) Background of AD; and (ii) TCIs in
AD. Hot topics in the treatment of AD not supported by meta-analysis, clinical trials or large observational studies were
also discussed based on clinical experience.
Results In total, 25 consensus statements were deﬁned and validated: eight statements on the general background of
AD and 17 statements on the use of TCIs in AD, including their mechanism of action and therapeutic indications in AD,
efﬁcacy in adult and paediatric AD patients, pharmacokinetics, incidence of adverse events and safety concerns. Hot
topics on the use of TCIs for the treatment of AD included cream vs. ointment, dosages, TCIs contact allergy, burning
sensation management, superinfection and vaccination concerns.
Conclusion Topical calcineurin inhibitors are a suitable therapy for AD, and selection of the speciﬁc TCI should be
based on factors which differentiate tacrolimus from pimecrolimus.
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Introduction
Atopic dermatitis (AD) represents the most common inflamma-
tory skin disease in both adults and children.1,2 It is a chronic
skin condition, with a major impact on the quality of life of
affected patients and their families.2,3
Figure 1 depicts a detailed treatment pathway for mild, mod-
erate and severe AD. Topical corticosteroids are considered the
first-line therapy for AD.4,5 However, their long-term use can be
associated with relevant side-effects, and patients may be reluc-
tant to continue this therapy given the risk of adverse events,
ultimately contributing to treatment failure.6–8
Two topical calcineurin inhibitors (TCIs), tacrolimus oint-
ment and pimecrolimus cream, have proven efficacy for the
treatment of AD.7 Whilst they are both inhibitors of calcineurin,
tacrolimus and pimecrolimus have distinct pharmacological and
efficacy profiles.7 Consequently, the selection of therapy should
rely mostly on field-practice experience and robust expert opin-
ion of existing evidence and factors able to differentiate between
the two drugs.6,7
Due to the burden of AD, it is important to involve experts to
obtain their opinion on its optimal treatment. This paper repre-
sents the final outcome of a European project aimed at obtain-
ing, using a modified Delphi approach, expert opinion to reach
consensus on TCIs in the treatment of AD, with a focus on the
differentiation between tacrolimus and pimecrolimus.
Methods
Six expert dermatologists from different European countries
participated in this project based on their experience with AD
and its treatment, which was evaluated by literature analysis and
expert opinion. Consensus amongst the experts was generated
by a modified Delphi approach, consisting of three distinct
phases: an Exploration phase, an Analytical phase and an Evalua-
tion phase.
Exploration phase
During the Exploration phase, the expert panel identified
objectives and arguments to be evaluated, detailed the
methodology, and prepared comprehensive documentation of
research questions and preliminary statements based on the
literature. An online meeting was conducted (June 2017)
during which general background consensus statements were
defined based on expert opinion and literature data. Litera-
ture research was conducted using the following databases:
PubMed/MEDLINE/PreMEDLINE. Relevant articles were
identified based on specific selected criteria/keywords with
reproducible methods (see Appendix).
The consensus statements concerned two main topics: (i)
Background of AD; and (ii) TCIs in AD, which was separated
into five research questions: (i) What about the mechanism of
action and therapeutic indications in AD? (ii) What about effi-
cacy in adult and paediatric AD patients? (iii) What about phar-
macokinetics? (iv) What about the incidence of adverse events?
and (v) What about the safety concerns?
Hot topics in the treatment of AD not supported by meta-
analysis, clinical trials or large observational studies (i.e. without
major literature evidence) were also identified.
Analytical phase
This phase involved statement processing based on expert opi-
nion and literature data. The first round of online Delphi voting
was conducted. In total, two rounds of online Delphi voting
were conducted (July–September 2017), with participants
blinded to the results of other experts. A secure website (survey
monkey.com) was used for the online voting, with Verisign cer-
tificate version 3, 128-bit encryption.
The degree of consensus for each statement was assessed using
a 5-point unipolar Likert scale: agreement was set at a cut-off of
80% of positive responses (corresponding to scores 4 and 5 on
the Likert scale).
Evaluation phase
Delphi results from round 1 voting were submitted to the
expert panel for evaluation, and statements were modified
according to participants’ feedback and were then voted on
again in their modified form during the second round of
online Delphi voting. Lastly, a face-to-face meeting was con-
ducted in November 2017 during which the final consensus
statements were selected, based on the pre-identified cut-off
value of 80%, expert opinions on hot topics in the treatment
of AD without major literature evidence were collected, and
Mild AD
Emollients, mild and midpotent TCS, pimecrolimus
Moderate AD
Midpotent and potent TCS, tacrolimus, 
emollients, UV-therapy 





CsA, MTX, AZA, 
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Figure 1 Treatment pathway for mild, moderate and severe ato-
pic dermatitis (AD). AZA, azathioprine; CsA, cyclosporine A; MTX,
methotrexate; TCS, topical corticosteroids; UV, ultraviolet.
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‘field-practice’ clinical experience and real-life clinical data
were discussed.
It should be highlighted that a Delphi consensus is not a
method for introducing new or better evidence, and it only pro-
poses a process to identify rational choices on important topics.
Strengths and limitations of the modified Delphi approach
include the following. Firstly, although there were a relatively
small number of selected expert panelists, the participation of
opinion leaders from multiple countries granted broader sharing
and increased the consistency of the structured report. Secondly,
the discussion between scientific board members may have influ-
enced the expert opinion leading to higher percentages of final
agreement. Thirdly, more recent data may have been published
subsequent to the literature search, which was performed in June
2017.
The entire project was handled by a professional agency (Hip-
pocrates, Genoa, Italy), which provided support for the litera-
ture research and in conducting meetings and Delphi rounds.
Consensus statements and Delphi results
After two rounds of voting, all statements reached final consen-
sus. In total, 25 consensus statements were defined and vali-
dated: eight statements on the general background of AD and 17
statements on the use of TCIs in AD, including their mechanism
of action, efficacy, pharmacokinetics, incidence of adverse events
and safety concerns. The final version of the statements for each
topic and research question, and the level of consensus achieved
are depicted in Tables 1–6.
A detailed comment on the statements is provided below.
Table 1 Consensus statements on the general background of atopic dermatitis (AD)
Statement Consensus reached (%)
1A AD is an inﬂammatory, itching, chronic or chronically relapsing skin disease 100
1B AD is one of the most common skin diseases which affects adults and mainly children in most countries of the world
and which occurs often in families with history of other atopic diseases (bronchial asthma and/or allergic rhinoconjunctivitis)
100
1C After establishing the diagnosis of AD, the severity of the disease has to be determined. The standard approach is the
‘Scoring of Atopic Dermatitis’ (SCORAD). Another commonly used scale to assess disease severity is the Eczema
Area and Severity Index (EASI).
**SCORAD (<25 mild AD, ≥25 and ≤50 moderate AD, >50 severe AD).
EASI (≤7 mild AD, >7 and ≤21 moderate AD, >21 severe AD)
100
1D Management of exacerbated AD is a therapeutic challenge, as it requires effective short-term control of
acute symptoms, without compromising the overall management plan that is aimed at long-term stabilization,
ﬂare prevention and avoidance of side-effects
100
1E Anti-inﬂammatory treatment based on topical glucocorticosteroids (GCs) and topical calcineurin inhibitors
(TCIs) is used for the management of exacerbations and, more recently, for proactive therapy in selected cases
83.33
1F Topical GCs remain the mainstay of therapy with fast and effective action. However, they are associated with some
adverse effects, especially over the long-term period. In contrast, tacrolimus has a more speciﬁc mechanism
of action and TCIs, due to their high afﬁnity for the receptor and lower absorption through skin, do not cause such events.
TCIs are especially indicated in long-term therapies and are preferred in certain sensitive areas (TCIs are
especially indicated in challenging areas such as the face, intertriginous sites and anogenital area)
100
1G TCIs should be used as a second-line drug following topical GCs 83.33
1H The anti-inﬂammatory potency of tacrolimus ointment is similar to that of a
corticosteroid with moderate activity, whilst the latter is more active than pimecrolimus cream
100
Table 2 Consensus statements on the mechanism of action and




2A There are two TCIs available for AD treatment:
tacrolimus 0.03% or 0.1% ointment and 1.0%
pimecrolimus cream
100
2B Tacrolimus is indicated in moderate-to-severe AD
(ﬂares and maintenance treatment based on SmPC).
Tacrolimus can be used for the prevention of ﬂares
and to prolong ﬂare-free intervals
in patients experiencing a high frequency
of disease exacerbations (i.e. occurring
four or more times per year)
100
2C Pimecrolimus is indicated in mild or moderate AD
and can be used intermittently in the long term for the
prevention of progression to ﬂares
83.33
2D TCIs suppress synthesis of pro-inﬂammatory
cytokines. In the cytoplasm of the target cells,
pimecrolimus and tacrolimus
bind to the intracellular protein
macrophilin-12, also called FKBP.
Tacrolimus shows
a threefold greater afﬁnity to FKBP
compared with pimecrolimus
100
2E TCIs immunosuppressive activity results from
suppressing calcineurin activity. The drugs have an
anti-inﬂammatory activity due to T-helper activity
affecting synthesis and release of pro-inﬂammatory
cytokines. Tacrolimus and pimecrolimus inhibit mast
cell and neutrophil activation and release of
inﬂammatory mediators. Tacrolimus affects basophil
and eosinophil function as well as function
and induction of apoptosis in Langerhans cells
100
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Evidence-based comment
Background of AD
In this general overview, the participants agreed on basic defini-
tions of the disease and management strategy. AD was defined as
an inflammatory, itching, chronic or chronically relapsing skin
disease, with a very high prevalence affecting adults and mainly
children in most countries of the world. It often occurs in fami-
lies with a history of other atopic diseases, including bronchial
asthma and/or allergic rhinoconjunctivitis.9,10
After AD has been diagnosed, disease severity has to be deter-
mined using dedicated scales. The standard approach is the
‘Scoring of Atopic Dermatitis’ (SCORAD),10 but another com-
monly used scale to assess disease severity is the Eczema Area
and Severity Index (EASI).11
Management of exacerbated AD represents a major therapeu-
tic challenge, requiring effective short-term control of acute
symptoms whilst maintaining the overall management plan of
long-term stabilization, flare prevention and avoidance of side-
effects.9 To this end, anti-inflammatory treatment based on topi-
cal corticosteroids and TCIs should be used for the management
of exacerbations and the proactive therapy of selected cases.9,10
TCIs should be used for the management of exacerbations and
continued with twice-weekly proactive therapy twice weekly for
Table 3 Consensus statements on the efﬁcacy of topical cal-




3A The efﬁcacy of both tacrolimus ointment
and pimecrolimus cream has been demonstrated
vs. placebo in clinical trials,
in both the short- and long-term settings.
In addition, proactive tacrolimus ointment therapy
has been shown to be safe and effective
for up to 1 year in reducing the number of ﬂares
and improving the quality of life
in adult patients and children
100
3B Well-grounded evidence shows
that in adult and paediatric AD patients,
tacrolimus ointment is more effective
than pimecrolimus cream,
with a faster onset of action
100
3C Data from adult and paediatric studies in patients
with mild, moderate and severe disease support the
superior efﬁcacy of tacrolimus ointment
when compared with pimecrolimus cream
in the treatment of AD
100
Table 4 Consensus statements on the pharmacokinetics of
topical calcineurin inhibitors (TCIs)
Statement Consensus
reached (%)
4A TCI absorption through the skin into circulation is
minimal due to the large molecular size of the drugs.
Pimecrolimus is more lipophilic than tacrolimus, and
this results in slow penetration of TCI from the
corneal layer rich in lipids into the hydrated lower
epidermal layer
83.33
4B Pimecrolimus permeates through the skin less than
tacrolimus. Nevertheless, data from adult and
paediatric pharmacokinetic studies show that
tacrolimus ointment is associated with minimal
systemic absorption and has no evidence of
systemic accumulation in adult and paediatric
patients with moderate-to-severe atopic dermatitis
and extensive disease
100
Table 5 Consensus statements on the incidence of adverse
events with topical calcineurin inhibitors
Statement Consensus
reached (%)
5A Data from studies in adults and children with mild,
moderate and severe disease show that the
incidence of adverse events, including local
application site reactions, was low and comparable
in tacrolimus-treated and pimecrolimus-treated
patients
100
Table 6 Consensus statements on the safety concerns with the
use of topical calcineurin inhibitors (TCIs) in atopic dermatitis (AD)
Statement Consensus
reached (%)
6A Burning sensation is a very common undesirable
effect with both TCIs, with frequencies ≥1/10.
Usually, it is of mild-to-moderate severity and tends
to resolve within 1 week of treatment initiation
100
6B In AD adult patients, there were no signiﬁcant
differences in the incidence of adverse events,
including application site burning, between
tacrolimus and pimecrolimus. No safety concerns
were observed
83.33
6C In AD paediatric patients, there were no signiﬁcant
safety and tolerability differences between tacrolimus
and pimecrolimus
83.33
6D Lymphoma incidence in TCI-treated patients was no
higher than in the general population, and no causal
relationship has been demonstrated between TCI
use and an increased risk of lymphoma
100
6E Epidemiological and clinical data challenge the
validity of the warning placed on TCIs, which is
based on theoretical concerns about a potentially
associated risk of lymphoma. The American
Academy of Dermatology (AAD) believes that these
warnings confuse and unnecessarily worry people.
Studies prove that with proper use, TCIs are not
dangerous
100
6F There is no scientiﬁc evidence of an increased risk of
malignancy due to a topical treatment with TCIs
100
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several months. Unlike topical corticosteroids, TCIs are not
associated with skin atrophy over the long-term use.12,13 In a
comparative study on quiescent AD, 4-week treatment with a
corticosteroid (betamethasone valerate) adversely affected the
biophysical properties of the skin barrier and reduced the
concentration of natural moisturizing factors; on the other
hand, tacrolimus improved skin barrier and increased hydra-
tion to levels similar to those of healthy skin.14 Therefore,
TCIs are specifically indicated in the long-term treatment of
AD for the whole body and are preferred in certain sensitive
areas including the face, intertriginous sites and anogenital
area.9,10,15
What about the mechanism of action and therapeutic
indications in AD?
At present, two TCIs are available for the treatment of AD in
clinical practice: tacrolimus ointment available in two strengths
(0.03% and 0.1%) and pimecrolimus available as a 1.0%
cream.15 Tacrolimus is indicated in moderate-to-severe AD for
short-term treatment and long-term intermittent treatment of
flares as well as for proactive therapy for the prevention of
flares.16 When used as maintenance therapy, tacrolimus has been
shown to prolong flare-free intervals in patients who experience
a high incidence of disease exacerbations (i.e. occurring four or
more times per year). Pimecrolimus is indicated in mild-to-
moderate AD.17 Although pimecrolimus is not licensed for
proactive management, it may be used in the prevention of acute
exacerbation of the disease and can be used intermittently with
corticosteroids.17
The mechanism of action of TCIs is to suppress synthesis of
pro-inflammatory cytokines. Pimecrolimus and tacrolimus bind
to the intracellular protein macrophilin-12, also known as FKBP,
in the cytoplasm of target cells.15 It is noteworthy that affinity to
FKBP is threefold greater for tacrolimus compared with pime-
crolimus.18 Moreover, TCIs exert an immunosuppressive action
by suppressing the activity of calcineurin and inhibiting mast cell
and neutrophil activation. Considering the target cells involved
in the action of TCIs, pimecrolimus exerts an action on T lym-
phocytes and mast cells whilst tacrolimus also reduces function
of basophils and eosinophils and induces apoptosis of Langer-
hans cells.15 In this way, tacrolimus has a broad spectrum of
activity on the immune system.
What about efﬁcacy in adult and paediatric AD patients?
Tacrolimus ointment and pimecrolimus cream have demon-
strated efficacy in clinical trials in both short- and long-term
therapy of AD.7,19–22 However, a detailed description of results
from these trials is beyond the scope of the present paper. In
addition, proactive treatment of AD with 0.1% tacrolimus oint-
ment for up to 1 year was shown to be effective and safe with a
significantly reduced number of flares (P < 0.001 compared
with vehicle ointment) and improved quality of life in adult
patients.22
Tacrolimus ointment was found to be more effective than
pimecrolimus cream in adult and paediatric patients with AD in
a Cochrane meta-analysis which included 20 studies, with 5885
participants.6 These findings are consistent with AD of varying
degrees of severity and in adult and paediatric patients.23,24 In a
head-to-head study, tacrolimus treatment induced significantly
greater improvements in the EASI score by week 3 compared
with pimecrolimus, with improvements sustained until study
end (a reduction of 57% from baseline with tacrolimus vs. 39%
with pimecrolimus, P = 0.0002).25
What about pharmacokinetics?
The large molecular size of TCIs minimizes their absorption
through the skin into circulation. Importantly, pimecrolimus is
highly lipophilic, which results in its slow penetration from the
corneal layer rich in lipids into the hydrated lower epidermal
layer.15 TCIs are associated with minimal systemic absorption,
with no evidence of systemic accumulation in adult and paedi-
atric pharmacokinetic studies.26
What about the incidence of adverse events?
A similar low incidence of adverse events, including local appli-
cation site reactions, has been demonstrated in adult and paedi-
atric patients with mild to very severe AD treated with either
tacrolimus or pimecrolimus.24 Burning sensation is a common
undesirable event with both TCIs. It is usually mild-to-moderate
in severity and tends to resolve within 1 week after treatment
initiation.16,17 No differences were identified in the incidence of
adverse events, including application site burning, in adult
patients treated with either tacrolimus or pimecrolimus25; simi-
lar findings have been reported in paediatric patients.7,27 In
addition, studies have shown that there is no increased risk in
cutaneous infections (including herpes) in patients treated with
tacrolimus.6
What about safety concerns?
An increased background incidence of lymphoma has been
regarded as a safety concern in patients treated with TCIs.28 How-
ever, it has been demonstrated that the incidence of lymphoma in
TCI-treated patients is no higher than in the general population,
and no causal relationship has been demonstrated between TCI use
and an increased risk of lymphoma.29 Moreover, epidemiological
and clinical data challenge the validity of the warning issued by the
United States Food and Drug Administration on TCIs, which is
based on theoretical concerns about a potentially associated risk of
lymphoma.29,30 To this end, the American Academy of Dermatol-
ogy believes that ‘these Warnings confuse and unnecessarily worry
people. Studies prove that with proper use, topical pimecrolimus
and tacrolimus are not dangerous’.29
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Clinical experience on hot topics not addressed in
major literature
The participants also discussed current hot topics concerning
the use of TCIs for the treatment of AD which, by their nature,
cannot be formally addressed in clinical trials or large observa-
tional studies. The key outcomes of this discussion are provided
below.
Cream vs. ointment
Delivery vehicles play a major role in contributing to the efficacy
and safety of topical treatments in the dermatological set-
ting.31,32 Of the two TCIs available for the treatment of AD,
tacrolimus ointment and pimecrolimus cream, the lipophilic
properties of an ointment permit better penetration and enhance
moisturizing activity due to its higher concentration of oil com-
pared with a cream-based treatment. Indeed, AD can be consid-
ered a dry skin condition, and the use of tacrolimus ointment
may aid healing by keeping the skin moist for longer. Therefore,
in some skin conditions, such as AD, it may be preferable to ini-
tiate treatment with an ointment given its moisturizing activity
that can help deliver a rapid response. However, for some speci-
fic sites (e.g. face, and especially during summer), patients may
prefer an agent characterized by a lower activity but with a more
comfortable application, such as a cream. Clinicians should be
aware of these potential differences and tailor therapy accord-
ingly, with the aim to ensure proper compliance.
Tacrolimus multiple strength vs. pimecrolimus single
dosage
The availability of two dosages of tacrolimus may offer more
flexibility in clinical practice compared with the single dosage
available for pimecrolimus. Indeed, the 0.03% tacrolimus for-
mulation shows high efficacy in the treatment of children with
mild-to-moderate AD.33 However, the more potent 0.1% for-
mulation of tacrolimus may also be needed in children, espe-
cially in particular cases such as the treatment of lichenified
lesions on the extremities. Treatment with tacrolimus 0.1% is
recommended in adult patients, and the 0.03% formulation is
effective in mild-to-moderate AD and in AD located on the eye-
lid.33 The double formulation allows such flexibility in the
choice of the treatment, for the specific indication required.
TCIs contact allergy
Contact allergy has been anecdotally reported in association with
TCI treatment.34–37 It appears that most cases of contact allergy
were related to pimecrolimus use, possibly due to the presence
of cetyl alcohol, stearyl alcohol or polypropylene glycol, which
are known to cause contact dermatitis.36,38 However, the partici-
pants agreed in not considering contact allergy as differentiating
issues between the two TCIs, because of the poor evidence avail-
able in the literature and the well-established safety profile of
both compounds in clinical practice. Therefore, contact allergy
should not be considered a safety concern for TCI therapy in AD
patients.
Burning sensation management
Some patients, almost all cases in adults, experience a burning
sensation during TCI therapy.39,40 This sensation, which is likely
related to mast cell activity, has an intensity associated with
disease severity and long-term previous therapy with corticos-
teroids.41
It is noteworthy that the burning sensation tends to resolve
within 1 week of treatment initiation, and therefore, patients
should be educated to not interrupt therapy with TCIs if this
event occurs; by continuing therapy, the skin barrier improves
and the intensity of the burning sensation decreases.40,42 If nec-
essary, the administration of non-steroidal anti-inflammatory
drug (e.g. ibuprofen) or paracetamol can be recommended dur-
ing the first days of treatment with tacrolimus to reduce the
burning sensation. Moreover, the use of acetylsalicylic acid was
shown to be very efficient in one study.43
Superinfection
Patients with active eczema often present Staphylococcus aureus
superinfection, which may require antibiotic therapy; however,
when the lesions heal, the infection regresses due to the restored
skin barrier.
Table 7 Factors differentiating tacrolimus from pimecrolimus,
according to participants’ opinion and current evidence
More favourable pharmacokinetic (e.g. higher penetration in the skin) and
pharmacodynamic (e.g. higher afﬁnity for FKBP) properties of tacrolimus
compared with pimecrolimus
Superior efﬁcacy of tacrolimus as compared with pimecrolimus according
to current clinical evidence
Fast and sustained action of tacrolimus
The ointment formulation of tacrolimus could be an advantage over cream
formulation
Potential role of tacrolimus within combination regimens with
corticosteroids
Figure 2 Outcome of a 1-week treatment with tacrolimus oint-
ment in a paediatric patient with atopic dermatitis.
© 2018 European Academy of Dermatology and VenereologyJEADV 2018, 32, 2074–2082
TCIs in atopic dermatitis 2079
Vaccination concern
The participants agreed that there is no relationship between
TCI application and vaccination efficacy, in line with previous
reports.44,45
Expert opinion: differentiation between TCIs in
clinical practice
According to available evidence and the participants’ opinion,
TCIs can represent a suitable therapy for AD. Selection of the
specific TCI should be based on a number of factors which dif-
ferentiate tacrolimus from pimecrolimus (Table 7).
Firstly, the choice of tacrolimus treatment is driven by its
superior efficacy compared with pimecrolimus, likely due to its
more favourable pharmacodynamic properties such as greater
affinity for FKBP. This high efficacy has a prompt onset of action
and is sustained over the long term, with proactive treatment
contributing to normalize the skin condition without any rele-
vant safety concerns or damage to the skin (Figs 2 and 3).
Tacrolimus is effective in sensitive and non-sensitive areas, with
the only possible exception being hand eczema, a condition in
which tacrolimus is often not effective enough.
Notably, long-term results with tacrolimus are better if treat-
ment is used as monotherapy, as this leads to a normalization of
the skin barrier. If corticosteroids are used together with tacroli-
mus, they may reduce inflammation but weaken the skin barrier
at the same time. The only exception is hand eczema, where
tacrolimus is often not effective enough, probably due to the
thickness of the skin (Fig. 4).
Importantly, an ointment formulation could be an advantage
in several cases, according to disease severity and the involve-
ment of specific body areas. In particular, ointments may grant a
more evident moisturizing effect and therefore may be suitable
for the treatment of AD. Collectively, these properties of tacroli-
mus may result in a greater efficacy and be associated with a
cost-saving for the healthcare system, as compared with pime-
crolimus.46 Consequently, tacrolimus may be considered favour-
ably for the treatment of AD in both adult and paediatric
patients.
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Appendix: Search criteria
(‘Dermatitis, Atopic’[Majr] OR ‘atopic dermatitis’[tiab] OR
‘atopic eczema’[tiab] OR ‘atopic eczemas’[tiab] OR ‘infantile
eczema’[tiab] OR ‘atopic neurodermatitis’[tiab] OR ‘dissemi-
nated neurodermatitis’[tiab] OR (atopic[tiab] AND (dermatitis
[tiab] OR eczema*[tiab] OR dermatitides[tiab]))) AND
(‘Calcineurin Inhibitors’[Majr] OR ‘Tacrolimus’[Majr] OR
‘pimecrolimus’ [Supplementary Concept] OR ‘topical cal-
cineurin inhibitors’[tiab] OR ‘topical calcineurin inhibitor’[tiab]
OR TCIs[tiab] OR TCI[tiab] OR tacrolimus[tiab] OR pime-
crolimus[tiab] OR ‘calcineurin inhibitors’[tiab] OR ‘calcineurin
inhibitor’[tiab] OR ‘calcineurin antagonist’[tiab] OR ‘cal-
cineurin antagonists’[tiab] OR (calcineurin*[tiab] AND
(antagonist*[tiab] OR inhibitor*[tiab])))) AND ((Clinical
Study[ptyp] OR Clinical Trial[ptyp] OR Consensus Develop-
ment Conference[ptyp] OR Consensus Development Confer-
ence, NIH[ptyp] OR Guideline[ptyp] OR Meta-Analysis[ptyp]
OR Practice Guideline[ptyp] OR systematic[sb] OR Review
[ptyp])))) OR ((‘Dermatitis, Atopic’[Majr] OR ‘atopic dermati-
tis’[tiab] OR ‘atopic eczema’[tiab] OR ‘atopic eczemas’[tiab] OR
‘infantile eczema’[tiab] OR ‘atopic neurodermatitis’[tiab] OR
‘disseminated neurodermatitis’[tiab] OR (atopic[tiab] AND
(dermatitis[tiab] OR eczema*[tiab] OR dermatitides[tiab])))
AND (‘Calcineurin Inhibitors’[Majr] OR ‘Tacrolimus’[Majr]
OR ‘pimecrolimus’ [Supplementary Concept] OR ‘topical cal-
cineurin inhibitors’[tiab] OR ‘topical calcineurin inhibitor’[tiab]
OR TCIs[tiab] OR TCI[tiab] OR tacrolimus[tiab] OR pime-
crolimus[tiab] OR ‘calcineurin inhibitors’[tiab] OR ‘calcineurin
inhibitor’[tiab] OR ‘calcineurin antagonist’[tiab] OR ‘cal-
cineurin antagonists’[tiab] OR (calcineurin*[tiab] AND (antag-
onist*[tiab] OR inhibitor*[tiab]))) AND (inprocess[sb] OR
publisher[sb]))
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